Suppr超能文献

肝衰竭患者的生存增加和肝重症监护中的器官衰竭和慢性肝衰竭-序贯器官衰竭评分系统的验证。

Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System.

机构信息

Institute of Liver Studies, Kings College Hospital, London, United Kingdom; Department of Hepatology and Gastroenterology, St Mary's Hospital Campus, Imperial College, London, United Kingdom.

Institute of Liver Studies, Kings College Hospital, London, United Kingdom.

出版信息

Clin Gastroenterol Hepatol. 2015 Jul;13(7):1353-1360.e8. doi: 10.1016/j.cgh.2014.08.041. Epub 2014 Sep 21.

Abstract

BACKGROUND & AIMS: During the past decade, survival has increased among patients admitted to general intensive care units, but it is not clear if it has increased for patients admitted with cirrhosis and organ failure. The chronic liver failure-sequential organ failure assessment (CLIF-SOFA) recently was developed as an adaptation to the SOFA to predict outcomes of patients, but requires validation. We investigated changes in outcomes of patients with cirrhosis and organ failure since 2000, compared the abilities of SOFA and CLIF-SOFA to predict patient survival, and validated the CLIF-SOFA system.

METHODS

In a retrospective study, we collected data from 971 patients (median age, 52 y; age range, 16-90 y; 62% male) with cirrhosis (54% alcohol associated, 12% viral, and 34% other causes). The patients were admitted under emergency conditions from January 1, 2000, to December 31, 2010, to a liver intensive therapy unit in the United Kingdom. Patient survival while in the hospital was compared with measures of illness severity, Acute Physiology and Chronic Health Evaluation (APACHE) II scores, model for end-stage liver disease (MELD) scores, SOFA scores, and CLIF-SOFA scores.

RESULTS

Patients had a median APACHE II score of 21 (range, 5-50) and a median MELD score of 23 (range, 6-40). The median APACHE II score at admission decreased from 23 to 22 over the study period (P < .001), whereas the median MELD score at admission decreased from 23 to 18 (P < .001). Overall survival until hospital discharge was 51%; this value increased from 40% in 2000 to 63% in 2010 (P < .001). The unadjusted odds ratio for change in mortality/year was 0.87 (95% confidence interval, 0.83-0.91; P < .001). The APACHE II score adjusted odds ratio for mortality was 0.89 (95% confidence interval, 0.84-0.93; P < .001). The etiology of cirrhosis was not associated with a significant difference in survival. CLIF-SOFA and SOFA scores at the time of admission predicted patient survival with area under the receiver operating curve (AUROC) values of 0.813 and 0.799, respectively; the scores at 48 hours after admission predicted survival with AUROC values of 0.853 and 0.840, and scores after 1 week predicted survival with AUROC values of 0.842 and 0.844, respectively. These AUROC values were higher than those obtained from APACHE II or MELD scores.

CONCLUSIONS

The proportion of patients with cirrhosis who survived after admission to intensive care increased from 2000 to 2010. SOFA and CLIF-SOFA scores during the first week of critical care appear to have similar abilities to predict patient survival.

摘要

背景与目的

在过去的十年中,入住普通重症监护病房的患者的存活率有所提高,但尚不清楚是否也提高了患有肝硬化和器官衰竭的患者的存活率。慢性肝脏衰竭-序贯器官衰竭评估(CLIF-SOFA)最近被开发为预测患者结局的 SOFA 适应指标,但需要验证。我们调查了自 2000 年以来患有肝硬化和器官衰竭的患者结局的变化,比较了 SOFA 和 CLIF-SOFA 预测患者生存率的能力,并验证了 CLIF-SOFA 系统。

方法

在一项回顾性研究中,我们收集了 971 名(中位年龄 52 岁;年龄范围 16-90 岁;62%为男性)患有肝硬化(54%酒精性,12%病毒性,34%其他原因)的患者的数据。这些患者因紧急情况于 2000 年 1 月 1 日至 2010 年 12 月 31 日期间入住英国的肝脏重症监护病房。将患者在医院期间的生存率与疾病严重程度的测量值(急性生理学和慢性健康评估 [APACHE] II 评分、终末期肝病模型 [MELD] 评分、SOFA 评分和 CLIF-SOFA 评分)进行比较。

结果

患者的中位 APACHE II 评分为 21(范围 5-50),中位 MELD 评分为 23(范围 6-40)。研究期间,入院时的中位 APACHE II 评分从 23 降至 22(P<.001),而入院时的中位 MELD 评分从 23 降至 18(P<.001)。总的住院存活率为 51%;这一数值从 2000 年的 40%增加到 2010 年的 63%(P<.001)。死亡率/年的未调整比值比为 0.87(95%置信区间,0.83-0.91;P<.001)。APACHE II 评分调整后的死亡率比值比为 0.89(95%置信区间,0.84-0.93;P<.001)。肝硬化的病因与生存率无显著差异。入院时的 CLIF-SOFA 和 SOFA 评分预测患者生存率的曲线下面积(AUROC)值分别为 0.813 和 0.799;入院后 48 小时的评分预测生存率的 AUROC 值分别为 0.853 和 0.840,入院后 1 周的评分预测生存率的 AUROC 值分别为 0.842 和 0.844。这些 AUROC 值高于 APACHE II 或 MELD 评分获得的值。

结论

2000 年至 2010 年,入住重症监护病房的肝硬化患者存活率有所提高。入住重症监护的第一周内的 SOFA 和 CLIF-SOFA 评分似乎具有相似的预测患者生存率的能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验